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Abstract
Background: Previous findings support the concept that IL-9 may play a significant role in mediating both pro-inflammatory
and changes in airway responsiveness that characterizes the atopic asthmatic state. We previously demonstrated that
human airway smooth muscle (ASM) cells express a functional IL-9R that mediate CCL11 expression. However, the signaling
pathway governing this effect is not well understood.
Methodology/Principal Findings: In this study, we showed that IL-9 mediated CCL11 expression in ASM cells does not rely
on STAT6 or STAT5 but on STAT3 pathway. IL-9 induced rapid STAT3 activation in primary ASM cells that was not observed
in case of STAT6 or STAT5. STAT3 binding to CCL11 promoter was also observed in vivo upon IL-9 stimulation of ASM cells.
Disruption of STAT3 activity with SH2 domain binding inhibitory peptide results in significant reduction of IL-9 mediated
CCL11 promoter activity. DN STAT3b over-expression in ASM cells, but not Ser 727 STAT3 or STAT6 DN, abolishes IL-9
mediated CCL11 promoter activity. Finally, STAT3 but not STAT6 silenced ASM cells showed significant reduction in IL-9
mediated CCL11 promoter activity and mRNA expression.
Conclusion/Significance: Taken together, our results indicate that IL-9 mediated CCL11 via STAT3 signalling pathway may
play a crucial role in airway inflammatory responses.
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Introduction
Airway smooth muscle (ASM) cells are key structural cells
involved in the pathogenesis of many airway diseases by
contributing to inflammation and airway hyperresponsiveness[1].
In addition to their proliferative and contractile properties, studies
suggest that ASM cells can contribute directly to the pathogenesis
of asthma by expressing cell adhesion and costimulatory molecules
and by secreting multiple proinflammatory cytokines and
chemokines that may perpetuate airway inflammation and the
development of airway remodeling in vivo[2].
IL-9 is a T cell derived cytokine with pleiotropic activities on
various cell types[3]. The expression of IL-9 is detectable mainly in
activated CD4+T cells. It has been shown that IL-9 can promote
the proliferation of activated and transformed T cells, the
production of immunoglobulins by B cells, the proliferation and
differentiation of mast cells, and erythroid progenitors[4]. A
number of observations have suggested that this cytokine may play
a role in asthma [4,5]. In humans, the IL-9 and IL-9R gene are
located on chromosomal region where a linkage with asthma and
its risk factors has been demonstrated[6,7].Moreover, the
development of transgenic mice over-expressing IL-9 has suggest-
ed a potential role for this cytokine in the development of airway
eosinophilia, mast cell hyperplasia, mucus production and airway
hyperresponsiveness[8,9,10]. Collectively, these findings support
the concept that IL-9 may significantly be involved in mediating
both pro-inflammatory and changes in airway responsiveness that
characterizes the atopic asthmatic state.
The intracellular signalling induced by IL-9/IL-9R on trans-
formed cell line has been characterized in details[11]. The binding
of IL-9 to IL-9R induces the activation of JAK1 which promotes
the phosphorylation of STAT1, 3 and 5[11,12]. Furthermore, IL-
9 can activate insulin receptor substrate -2 (IRS-2) pathway which
subsequently induces the activation of PI3K[13].
Previously, we showed that human ASM express a functional
IL-9R and activation through this pathway lead to CCL11
expression. We also documented IL-9R immunoreactivity in
smooth muscle bundle of atopic asthmatics bronchial biopsies
[14]. However the mechanism by which IL-9 mediates CCL11
expression in primary ASM cells is not fully understood. In this
report, we demonstrated that IL-9 mediates CCL11 gene
expression via a STAT-3 dependent pathway.
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IL-9 Induced CCL11 Gene Expression in ASM Cells Is
Independent of STAT-6 Activation
We have previously demonstrated that IL-9 induces CCL11
expression in ASM cells[14]. Furthermore, CCL11 expression has
been shown to be dependent on STAT-6 activation in various
inflammatory and structural cells including ASM cells [15]. To
determine STAT6 activation in response to IL-9 in ASM cells, total
cell protein was probed with specific anti phospho-tyrosine STAT6
and total STAT6. As shown in Fig. 1 A, IL-9 stimulation did not
induce STAT6 tyrosine phosphorylation over a 2 h time period in
ASM cells. However, as expected IL-4 used as positive control
induced a strong tyrosine phosphorylation of STAT6 (Fig. 1B).
Immunofluorescence coupled to confocal laser scanning mi-
croscopy was then preformed to determine STAT6 tyrosine-
phosphorylation and translocation to the nucleus in IL-9
stimulated ASM cells. IL-4, used as a positive control, demon-
strated noticeable STAT6 phosphorylation within 5 min in the
cytoplasm and nuclei of ASM cells (Figure 2A). However, IL-9 did
not induce noticeable STAT6 phosphorylation or translocation to
the nuclei in ASM cells (Figure 2B). This data suggests that IL-9
induction of CCL-11 release may not be dependent on STAT6
activation.
IL-9 Mediates CCL11 Expression in STAT6 Silenced ASM
Cells
To confirm our previous data, we investigated whether the
expression of CCL11 induced by IL-9 in ASM cells is affected by
the absence of STAT6 using a genetic approach. Primary human
ASM cells were transduced with a vector harboring STAT6-
shRNA or scramble shRNA. FACS analysis showed more than
95% of shRNA transduced cells were tGFP+ (Fig. 3A) and resulted
in a highly significant and reproducible decrease in STAT6
expression levels (Fig. 3B). Stably silenced STAT6 ASM cells were
transfected with CCL11 promoter and stimulated with IL-9
(10 ng/ml), or positive control IL-4 (10 ng/ml)[16]. IL-4 or IL-9-
induced transcriptional activation of CCL11 promoter was
unchanged in STAT6 or scramble silenced ASM cells (n=3,
p,0.05, Fig. 3C).
IL-9 Induces STAT3 Phosphorylation, Nuclei Translocation
and Binding to CCL11 Promoter in ASM Cells
Previous studies have shown the involvement of both STAT5
and STAT3 in IL-9 signaling pathway in transformed cell lines
[12,17,18]. To ascertain which STATs proteins were activated
following ASM cells stimulation with IL-9, we performed western
blot analysis using specific antibodies for the phosphorylated
regulatory sites on STAT3 and STAT5. As shown in figure 4A,
IL-9 induces rapid phosphorylation of STAT3 at Tyr705 within
5 min that diminishes afterward (Fig. 4A). No STAT5 phosphor-
ylation could be detected upon IL-9 stimulation. IL-4, used as
positive control, also induced a strong STAT3 phosphorylation
(Fig. 4B) as described in B cells [19].
We then performed chromatin immunoprecipitation (ChIP) to
investigate whether IL-9 stimulation induces STAT3 nuclei
translocation and binding in vivo to CCL11 promoter. Equal
amount of nuclear samples were immunoprecipitated with an
antibody against STAT3, and the immunoprecipitated DNA was
amplified with the specific human CCL11 primer pairs. The status
of the STAT3 transcription complex at CCL11 promoter in
response to IL-4 was used as positive control [16]. In contrast to
unstimulated cells, IL-9 induced a marked enrichment of STAT3
associated CCL11 promoter DNA, 197 bp region between 2136
to +61, at 30, 60 min which returned to baseline at 120 min
(Fig. 4C). In contrast, immunoprecipitation with isotype control
antibody resulted in the absence of a 197 bp band suggesting that
STAT3 specifically binds to CCL11 promoter. Furthermore, IL-4
treatment resulted in a clear enrichment of STAT3 at 30, 1 and
2 h (Fig. 4C) as we previously described[16]. These data suggest
that IL-9 induced CCL11 transcription involves in vivo STAT3
binding to CCL11 promoter.
We next used STAT3-specific reporter plasmid (pLucTKS3)
which harbors seven copies of a sequence corresponding to the
STAT3-specific binding site in the C-reactive gene promoter [20]
to confirm the activation of STAT3 mediated gene expression by
IL-9. As showed in figure 4D, both IL-9 and IL-4 are able to drive
STAT3 dependent luciferase promoter activity compared to
pLucTKS3 transfected unstimulated ASM cells (mean RLU 6
SD for IL-9: 5189764539; IL-4: 5931669458; med: 402316
8766; P,0.05, n=5). Furthermore, IL-9 and IL-4 are not able to
induce luciferase promoter activity when cells are transiently
transfected with pLucSRE serum response element (SRE) of the c-
fos promoter (mean RLU 6 SD for IL-9: 138617; IL-4: 125615;
med: 98623; n=5, P.0.05).
Figure 1. IL-9 does not induce STAT6 phosphorylation in
human ASM cells. Growth arrested ASM cells were stimulated with IL-
9 (A) or IL-4 (20 min,B) both at 10 ng/ml. Lysates were immunoblotted
with phospho-specific Abs and detected by enhanced chemilumines-
cence as described in Methods. Total STAT6 and b actin Abs was used
for loading control. The results represent one of similar results from four
independent experiments.
doi:10.1371/journal.pone.0009178.g001
Figure 2. IL-9 does not induce STAT6 nuclei translocation in
human ASM cells. Growth arrested semi-confluent ASM cells were
stimulated with IL-4 (A) or IL-9 (B) both at 10 ng/ml in 8 wells slide.
Slides were stained with specific anti- phospho tyrosine STAT-6 mAb or
isotype matched control, followed by goat anti-mouse IgG F(ab’)2
AlexaFluorH 488. Nuclear counter-staining was performed using TOTO-1
as described in Materials and Methods. Original magnification 400X.
doi:10.1371/journal.pone.0009178.g002
IL-9R in Smooth Muscle Cells
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STAT3 Dominant Negative Diminish IL-9 Mediated CCL-
11 Promoter Activity
Primary ASM cells were first pre-treated with STAT3 phospho-
peptide, a cell-permeable inhibitor that acts as a highly selective
potent blocker of STAT3 activation[21], transfected with CCL11
proximal promoter followed by IL-9 stimulation. As a negative
control, cells we pretreated with a STAT3 control peptide
(STAT3-CP) that has the same residue sequence without
phospho-group. As shown in figure 5, human ASM cells showed
a significant reduction (p,0.05) in CCL11 luciferase activity in
response to IL-9 stimulation following STAT3 inhibition with
STAT3-IP but not with STAT3-CP. STAT3-IP did not affect IL-
4 induced CCL11 promoter activity in ASM cells (Figure 5) as we
described previously [16].
We then examined the effect of a dominant negative STAT-3
DN (STAT3b), STAT6 DN and STAT3 mutant at serine 727 on
IL-9 mediated CCL-11 promoter activity in ASM cells. STAT3b
is a naturally occurring splice variant with a deletion in the C
terminal trans-activation domain that harbors the transcriptional
activation domain and the Ser 727 residue [22,23]. ASM cells co-
transfected with CCL11 promoter construct and STAT3b
expressing vector [20], but not with STAT3 mutant Ser 727,
showed a significant decrease in luciferase activity in response to
IL-9 stimulation (Fig. 6, n=5, p,0.001). Interestingly, cells co-
transfected with STAT3b expressing vector dispalyed a reduction
in luciferase activity in response to IL-4 but was statistically
significant (Fig. 6, n=5, p,0.001). Furthermore, co-transfection
with STAT-3 mutant at serine residu has no effect on IL-4
mediated CCL-11 promoter activity. This result suggests that
serine phosphorylation is not involved in IL-9 or IL-4 mediated
gene expression. Disruption of STAT6 function by co-transfection
of STAT6 dominant negative vector significantly decreases IL-4
but not IL-9 induced CCL11 promoter activity (p,0.05, n=5).
These results confirm that STAT3 activation is involved in IL-9
induced CCL11 promoter activity.
ShRNA Mediated STAT3 Silencing Abrogates IL-9
Mediated CCL11 Expression
We then used shRNA to human STAT3 to inhibit STAT3
expression in ASM cells (Fig. 6A) [16]. Mock and scramble
sequence was used as negative control. As revealed by FACS
analysis, the transduction efficiency of ASM cells was more than
95% as showed by the expression of turbo green fluorescent
protein reporter gene (tGFP+) (Fig. 7A). Moreover, STAT3
protein expression level was significantly reduced in STAT3-
shRNA transduced ASM cells, effect that was not observed with
scramble shRNA (Fig. 7B).
To determine if the transcriptional activation of CCL11 by IL-9
is affected in the absence of STAT3, stable STAT3 silenced ASM
Figure 3. IL-9 mediated CCL11 expression is not affected in STAT6 silenced ASM cells. A. Human ASM cells were transduced by infecting
with lentivirus containing scramble sequence, STAT6-shRNA sequence or mock and examined by flow cytometry for turbo GFP (tGFP) expression. B.
Effect of STAT6-shRNA on STAT6 expression by ASM cells. Expression of total STAT6 in mock, scramble or STAT6-shRNA transduced ASM cells was
analyzed by western blot. C. Stably silenced STAT6 ASM cells was co-transfected with CCL11 promoter then stimulated with IL-9 or IL-4 (both at
10 ng/ml) as described in Materials and Methods. The mean 6SE of three independent experiments are shown.
doi:10.1371/journal.pone.0009178.g003
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IL-9 (10 ng/ml), or IL-4 (10 ng/ml). IL-9 induced transcriptional
activation of CCL11 promoter was significantly reduced in STAT3-
shRNA transduced cells but unchanged in scramble transduced
cells (n=5, p,0.05). Furthermore, CCL11 promoter activity
induced by IL-4 was unaffected in STAT3 silenced ASM cells
(Fig. 7C) [16]. To confirm the specificity of our shRNA strategy,
STAT3 silenced ASM cells was also stimulated by IL-1b that is not
dependent on the STAT3 pathway. CC11 promoter activity
induced by IL-1b was similar in mock, scramble and STAT3
silenced ASM cells with a 3.260.5, 2.860.7 and 2.9560.36 fold
increase respectively compared to cells transfected with CCL11
promoter without IL-1b stimulation (data not shown).
Discussion
Our previous work showed that primary ASM cells express a
functional IL-9R in vitro; and in vivo ASM bundle from atopic
asthmatics displayed higher expression of IL-9R compared to
normal controls[14]. Activation of IL-9R in ASM cells mediated
CCL11 expression that can enhance eosinophil chemotaxis[14].
In this study, we aimed to define the role of STAT3 in IL-9
mediated CCL11 expression in ASM cells. Using different
strategies, we showed that IL-9 mediated CCL11 expression in
ASM cells requires STAT3 but not STAT6 pathway. IL-9
induced rapid STAT3 activation in primary ASM cells that was
not observed in case of STAT6 or STAT5. Furthermore, STAT3
Figure 4. IL-9 induces STAT3 phosphorylation and in vivo binding to CCL11 promoter in ASM cells. A–B. Cells were stimulated with IL-9
(A) or IL-4 (only 20 min is shown in B) and analyzed as described in Figure 1. The data represent one of similar results from 5 independent
experiments. C. IL-9 induced STAT3 binding to CCL11 promoter in vivo. Confluent and serum starved human ASM cells were treated with IL-4 (10 ng/
ml) or IL-9 (10 ng/ml). The in vivo STAT3 binding to the CCL11 promoter was analyzed by ChIP assay as described under Material and Methods. The
input represents PCR products from chromatin pellets prior to immunoprecipitation. The results are representative of three independent experiments
with similar results. D. IL-9 driven STAT3 reporter gene activity. STAT3-specific reporter plasmid (pLucTKS3) which harbors seven copies of a sequence
corresponding to the STAT3-specific binding site was transfected into ASM cells or with pLucSRE serum response element (SRE) of the c-fos promoter
(data not shown) following stimulation by IL-9 or IL-4 as described above. Data in D represent the mean 6 SEM from a total of 5 independent
experiments.
doi:10.1371/journal.pone.0009178.g004
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stimulation of ASM cells. Disruption of STAT3 activity with SH2
domain binding inhibitory peptide results in significant reduction
of IL-9 mediated CCL11 promoter activity. Naturally occurring
DN STAT3b [22,23] over-expression in ASM cells, but not Ser
727 STAT3 or STAT6 DN, abolishes IL-9 mediated CCL11
promoter activity. STAT3 but not STAT6 silenced ASM cells
showed significant reduction in IL-9 mediated CCL11 promoter
activity and mRNA expression. Our data strengthen the role of
STAT3 as a major player in IL-9 mediated CCL11 expression in
ASM cells.
CCL11 is a chemokine belonging to the CC family that has
been shown to be a potent chemoattractant for eosinophils both in
vitro and in vivo[24]. Increased production of CCL11 has been
associated with allergic diseases such as asthma[25]. Th-2
cytokines, particularly IL-4 can induce CCL11 release in many
structural cells including ASM cells [15,26]. Previously, it has been
demonstrated that human ASM cells express CCL11 following
pro-inflammatory cytokine stimulation [25]. The CCL11 pro-
duced and secreted by ASM cells may then amplify the chemokine
signal generated by infiltrating inflammatory cells in the airway,
thereby augmenting the recruitment of eosinophils, basophils, and
Th-2 lymphocytes to the airways[2]. The accumulation of these
inflammatory cells may subsequently contribute to the develop-
ment of airway hyperresponsiveness, local inflammation, and
tissue injury through the release of granular enzymes and other
cytokines. Our current study shows that IL-9 dependent activation
of ASM cells can induce CCL11 via STAT3 pathway, thus
revealing a new mechanism for induction of CCL11 within the
airways.
STAT3 is a member of cytokine and growth factor inducible
transcription factors. Upon phosphorylation at tyrosine residues,
STAT3 undergoes conformational change, dimerizes and trans-
locates to the nucleus where it can bind specific DNA motifs and
activate the transcription of distinct groups of genes [27]. Studies
using cell specific STAT3 KO indicates an important anti-
inflammatory role of STAT3 in innate immunity[28]. Further
evidences suggest a central role of STAT3 in regulating the anti-
inflammatory response in skin and liver pathological models
[28,29]. However, targeted disruption of STAT3 in airway
epithelial cells (e-STAT3-/-) showed a significant decrease of
airway eosinophilia suggesting an important role for STAT3 in
allergic inflammation [30]. Our present data extends these data by
showing that STAT3 activation is critical for IL-9 mediated
CCL11expression in ASM cells which may contribute to airway
inflammation.
Upon activation, STAT3 protein can be phosphorylated at both
Ser 727 and tyrosine 705 residues[27]. Our data showed that
STAT3 Ser727 mutation over-expression in ASM cells has no
effect on CCL11 gene expression. In transgenic mice expressing a
form of the STAT3 Ser727 mutant [31], tyrosine phosphorylation
of STAT3 was detected upon oncostatin M stimulation of
fibroblast; and many of the downstream signaling pathways
associated with STAT3 remain intact [31]. In vitro, similar results
were observed in STAT3 Ser727 mutant transfected cells[22].
Taken together, these data are in agreement with our findings and
suggest that STAT3 serine phosphorylation has no effect on
transcription of CCL11 gene in ASM cells upon IL-9 stimulation.
Besides STAT3, IL-9 has been shown to activate STAT1 and
STAT5 in malignant cell line. In our data however, IL-9 failed to
induce STAT1 (data no shown) or STAT5 phosphorylation.
Furthermore, co-transfection of STAT5DN in ASM cells did not
affect IL-9 mediated CCL11 promoter activity (data not shown).
In our study, IL-4 used as positive control induced STAT3
phosphorylation and recruitment to CCL11 promoter in vivo.
However, STAT3 inhibition by using inhibitory peptide, DN
STAT3b over-expression or shRNA targeting strategy failed to
demonstrate any role of STAT3 in mediating IL-4-induced
CCL11 promoter. This discrepancy can be explained by the fact
that IL-4 can induce both STAT6 and STAT3 activation in ASM
Figure 5. STAT3 inhibitory peptide decreases IL-9 mediated
CCL11 transcriptional activity. Human primary ASM cells were
growth-arrested, transfected with CCL11 promoter for 24 h. Cells were
then incubated with inhibitory or control peptide for 1 h before
stimulation for 12 hour with IL-4 or IL-9 after which transcriptional
activation was measured by luciferase activity. Fold induction
represents luciferase activity in cytokine treated cells compared to
transfected untreated cells, and is the mean of five independent
experiments. * P,0.05.
doi:10.1371/journal.pone.0009178.g005
Figure 6. Effect of DN STAT3b, STAT3 Ser 727, or DN STAT6
over-expression on IL-9 induced CCL-11 promoter activity.
Human primary ASM cells were co-transfected with WT-CCL-11
promoter and DN STAT3, STAT3b, STAT3 mutant at Ser 727 or DN
STAT6. 24 h after transfection, cells were stimulated for 12 h with IL-4 or
IL-9 (all at 10 ng/ml). Fold induction represents luciferase activity in
cytokine treated cells compared to transfected untreated cells, and is
the mean of five independent experiments. * P,0.05.
doi:10.1371/journal.pone.0009178.g006
IL-9R in Smooth Muscle Cells
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ASM cells [16]. Indeed, we confirmed that IL-4 can induce
STAT3 and STAT6 phosphorylation in ASM cells (Figure 1 and
4) and both can bind to the CCL11 promoter in vivo (Figure 4C).
As such, IL-4 can mediate CCL11 expression using STAT6 or
STAT3 dependent pathway in human ASM cells.
IL-9 has been shown to activate extracellular signal-regulated
kinases (ERK) in ASM cells[33]. Furthermore, the MAPKs have
been shown to play an important role in modulating STAT3
signaling. Specifically, ERK1/2 have been shown to phosphory-
late STAT3 at Ser 727 and to play a crucial role for transcriptional
activity [34,35]. Data from our lab showed that pharmacological
targeting of ERK1/2 inhibits IL-9 mediated CCL11 release and
promoter activity (Data not shown). These results are in agreement
with data by Baraldo et al. that demonstrated ERK1/2 activation
by IL-9 in ASM cells[33] and suggest a possible cross talk between
ERK and STAT3 pathway in ASM cells.
In summary, our study strengthens the role of STAT3 as a
major player in IL-9 mediated CCL11 expression. Our results also
highlight the importance of this pathway as a potential therapeutic
target in airway allergic inflammation.
Materials and Methods
Reagents and Antibodies
Recombinant human IL-9, IL-4, IL-1b, human recombinant
CCL11, anti-CCL11 capture mAbs and biotinylated detection
mAbs are from R&D (Minneapolis, MN). Mouse IgG1 isotype
control (clone MOPC21), and goat IgG were from Sigma
(Oakville, Ontario). FITC conjugated rat anti-mouse IgG was
from Jackson (West Grove, PA). Mouse IgG1 anti-phospho
tyrosine specific STAT-5 and STAT-6 were purchased from BD
(Mississauga, Ontario). Mouse mAb anti-phospho-tyrosine STAT-
3 (Y705), affinity purified rabbit anti-total STAT-3, STAT-5 and
STAT-6 were from Santa Cruz (Santa Fe, CA). Goat anti-mouse
IgG (Fab)’2 Alexa 488, nuclear TOTO stain were obtained from
Molecular Probes (Eugene, Oregon). Fetal bovine serum (FBS),
RPMI 1640 and antibiotics (penicillin, streptomycin) were from
Hyclone Laboratories (Logan, UT). Unless stated otherwise, all
other reagents were obtained from Sigma Chemical Co (Oakville,
Ontario).
Isolation and Culture of Human Airway Smooth Muscle
Cells
Human bronchial smooth muscle cells were obtained from
macroscopically healthy segments of 2
nd–4
th generation lobar or
main bronchus of patients undergoing surgery for lung carcinoma
in accordance with the procedures approved by the Ethics
Committee of the University of Manitoba, Winnipeg, Canada.
Informed consent for ASM harvesting was obtained from all
patients. Primary airway smooth muscle (ASM) cells were isolated
from explants as previously described[36]. Cells were cultured in
Dulbecco’s modified Eagle medium (DMEM) supplemented with
10% FBS, L-glutamine (2 mM), penicillin (100 U/ml), and
streptomycin (100 mg/ml) at 37uC with 5% CO2. At confluence,
primary human ASM cells exhibited spindle morphology and a
hill-and-valley pattern that is characteristic of smooth muscle in
Figure 7. Silencing STAT3 abrogates IL-9 mediated CCL11 expression. A. Efficiency of Lentiviral transduction in human ASM cells. Human
ASM cells were transduced by infecting with lentivirus containing scramble sequence or STAT3-shRNA sequence and examined by flow cytometry for
tGFP expression. B. Total STAT3 in mock, scramble and STAT3-ShRNA transduced ASM cells as analyzed by Western blot C. ASM cells stably
expressing scramble or STAT3-shRNA was transfected with CCL11 promoter luciferase reporter plasmid and stimulated with IL-9 (10 ng/ml) or IL-4
(10 ng/ml) as described in Methods. The mean 6SEM of three independent experiments are shown. * P,0.05 compared to scramble lentiviral
transduced ASM cells stimulated with IL-9.
doi:10.1371/journal.pone.0009178.g007
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specific actin, SM22, and calponin protein expression, and
mobilize intracellular Ca
2+ in response to acetylcholine, a
physiologically relevant contractile agonist[36].
Immunofluorescence and Confocal Laser Scanning
Microscopy (CLSM)
Serum fed human ASM cells grown on 8 well glass slides (Naig
Nunc, Napierville, IL) were cultured up 60–80% confluence. Cells
were then stimulated with IL-4 or IL-9 both at 10 ng/ml. Slides
were fixed with 4% paraformaldehyde, air-dried, and stored at
220uC until use. Slides were saturated with universal blocking
solution for 10 min (DakoCytomation, Carpenteria, CA). Slides
were incubated with 10 mg/ml of anti-phospho-tyrosine specific
anti-STAT6 mAb or isotype matched control (MOPC21) in
dilution buffer (Dako Cytomation) overnight at 4uC, washed twice
with Tris-Buffered Saline (TBS) followed by incubation for 1 h at
room temperature (RT) with goat anti-mouse IgG (Fab)’2
AlexaFluorH 488 (1:100 dilution) (Molecular Probe). Slides were
then extensively washed with TBS and counterstained with nuclei
stain TOTO for 2 min. After washing with TBS, the slides were
then mounted with anti-fad agent (Molecular Probe). Samples
were photographed on Olympus AX70 microscope with a
Photometrics PXL cooled CCD Camera and Image-ProH Plus
Software (Carsen Group Inc, Ontario).
Assessment of STAT3, STAT5, and STAT6 Phosphorylation
Nearly confluent ASM cells were growth arrested by FBS
deprivation for 48 h as described above. Cells were then
stimulated in fresh FBS free medium with IL-9 (10 ng/ml), IL-4
(10 ng/ml) or medium alone. At selected time points, the cells
were washed once with cold phosphate buffered saline (PBS), and
total proteins were extracted with lysis buffer (1% NP-40, PMSF,
2 mM sodium vanadate, 0.1% sodium deoxycolate, and protease
inhibitor cocktail (Roche, Penzberg, Germany). Harvested lysates
were centrifuged for 10 min at 4uC to pellet cellular debris. The
supernatants were removed and stored at 270C. Protein lysate
(10 mg) were loaded on 10% SDS PAGE, followed by transfer to
nitrocellulose membranes (Invitrogen). The blots were then
blocked with 5% non fat dry milk in TBS/0.1% Tween (TBST)
for 1 h at room temperature, and then incubated overnight at 4uC
with antibodies specific for phosphorylated STAT3 (Y705),
STAT5 (Y694) and STAT6 (Y641). After washing with TBST,
the blots were incubated with goat anti-mouse or goat anti rabbit
horseradish peroxidase conjugated secondary antibodies and
bands were revealed with ECL reagents (Amersham Pharmacia,
Baie D’Urfe, Quebec, Canada). After stripping, total anti- STAT3,
STAT5, STAT6 and b actin were used as loading control.
Luciferase Reporter Constructs and Cell Transfection
Plasmids expressing a dominant negative (DN) form of STAT3
(pSG5hSTAT3b) and a STAT3 mutant at serine 727 (S727A) were
kindly donated by Dr. R. Fostra (Royal Cancer Hospital, Brampton
UK) and Dr. R. Jove, (H. Lee Moffitt Cancer Center and Research
Institute, Tampa, Florida) respectively. A Stat3-specific reporter
plasmid (pLucTKS3) which harbors seven copies of a sequence
corresponding to the STAT3-specific binding site in the C-reactive
gene promoter (termed APRE, TTCCCGAA) and pLucSRE,
which contains two copies of the serum response element (SRE) of
the c-fos promoter both upstream from a firefly luciferase coding
sequenceweredonated byDr.J.Turkson[36] (UniversityofCentral
Florida College of Medicine, Orlando, FL). STAT6 DN and
eotaxin-1/CCL11-WT promoter luciferase construct were provid-
ed by J. Hoeck (Salzburg University, Austria)[14]. ASM cells
(4610
4) were seeded into 12-well culture plates in fresh complete
DMEM. After 24 h at 50–70% confluency, cells were transfected
transiently using ExGen 500 in vitro transfection reagent (Fermentas,
Ontario, Canada) according to the manufacturer’s instructions. In
eachwell, 1.6 mg of CCL11 promoter-luciferase DNAand 0.4 mgo f
Renilla luciferase reporter vector-pRL-TK (Promega) were co-
transfected for 24 h. In some experiments, DN STAT3, STAT6 or
STAT3 Ser 727 mutant were co-transfected with WT CCL11
promoter-luciferase DNA. Themediumwas changedand cellswere
washed and stimulated with IL-9 or IL-4 (both at 10 ng/ml). After
12 h of cytokine stimulation, cells were washed twice with PBS and
cell lysates were collected with 100 ml of reporter lysis buffer
(Promega). The luciferase activity was measured by the Dual-
Luciferase Assay System kit (Promega) using a luminometer (model
LB9501; Berthold Lumat). Briefly, 20 ml of cell lysate was mixed
with 100 ml of Luciferase Assay Reagent II (Promega) and firefly
luciferase activity was first recorded. Then, 100 ml of Stop-and-Glo
Reagent (Promega) was added, and Renilla luciferase activity was
measured. All values are normalized to Renilla luciferase activity and
expressed relative to the control transfected non stimulated cells.
Chromatin Immunoprecipitation (ChIP) Assay
Chromatin immunoprecipitation assay was done essentially as
described elsewhere[37], with minor modifications. Briefly, human
ASM cells in 90-mm dishes were grown to confluency and serum
starved for 48 h. Cells were then incubated with or without IL-9 or
IL-4 (both at 10 ng/ml) for 30, 60 or 120 min. The cells were
cross linked for 10 min with 1% formaldehyde in PBS to fix
protein-DNA complexes, washed and lysed in 200 ml of SDS-lysis
buffer (50 mM Tris, pH 8.0; 1% SDS; 5 mM EDTA; complete
proteinase inhibitor cocktail) and sonicated on ice. The samples
were then centrifuged for 10 minutes, and chromatin pellets were
sheared by sonication. Samples were pre-cleared with salmon
sperm DNA-saturated protein A agarose (Upstate Biotech,
Waltham, MA) for 1 h at 4uC with rotation. After centrifugation
at 5006g for 1 min, one portion of the soluble chromatin was used
as DNA input control, and the remains were sub-aliquoted and
then precipitated using specific antibodies, a non-immune rabbit
immunoglobulin G (IgG; Santa Cruz) or STAT3 rabbit mAb
separately, overnight at 4uC. Protein-bound immunoprecipitated
DNA was washed successively with low-salt buffer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.1],
150 mM NaCl), high-salt buffer (same as the low-salt buffer but
with 500 mM NaCl), LiCl buffer (0.25 M LiCl, 1% NP-40, 1%
deoxycholate, 1 mM EDTA, 10 mM Tris-HCl [pH 8.1]), and
Tris-EDTA (pH 8.0) and then eluted with elution buffer (1% SDS,
100 mM NaHCO3). The elution (cross-linking of protein-DNA
complexes) was reversed by incubation with 5 M NaCl at 65uC for
4 h, and then incubated for 1 h at 45uC with 10 mg of proteinase
K (Sigma) per ml. DNA was then extracted with phenol-
chloroform, precipitated with ethanol, and resuspended in 20 ml
of TE buffer. The DNA from both sample and input was amplified
by semi-quantitative PCR (30 cycles) using the primers specific for
the CCL11 promoter (–136 to +61) encompassing both STAT and
NF-kB binding sites. Primer pairs of CCL11 promoter are:
forward, 59-CTTCATGTTGGAGGCTGAAG-39, and reverse,
59-GGATCTGGAATCTGGTCAGC-39. PCR products were
resolved by using 3% agarose gel and visualized with ethidium
bromide.
Inhibitory Peptide
A cell-permeable STAT3 peptide inhibitor that consist of H-
PY*LKTK-AAVLLPVLLAAP-OH, and control peptide 2) H-
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ly[21]. The control peptide is identical in sequence to the inhibitor
except that the tyrosine residue, which is essential for the
inhibitory action, is not phosphorylated[21]. The peptides were
synthesized by the Bio S&T Company (Montreal, Quebec,
Canada). Peptides were used at concentrations of 500 mM[21].
Lentiviral Vector Transduction in Human ASM Cells
293T cells used for virus production and titration were cultured
in Iscove’s modified Dulbecco’s medium (HyClone, Logan, UT)
supplemented with 10% fetal bovine serum (FBS), and 1%
penicillin/streptomycin/glutamate (PSG) (Gibco, Grand Island,
NY). Lentiviruse were generated and titrated using 293T cell lines
as previously described [38]. For gene silencing, a clone specific for
STAT3 (clones Id: V2LHS_262105, V2LHS_88502) was ob-
tained from Open-Biosystems (Huntsville, AL). A control scram-
bled shRNA unrelated to STAT3 or STAT6 sequences was used
as a negative control for lentiviral transduction. For all gene
silencing studies, ASM cells were transduced at 10 infectious unit
per ml in the presence of polybrene (8 mg/ml). In brief, cells were
exposed to recombinant lentivirus for 2 hr at 37u C, medium
replaced and cultured for additional 72 hrs. Transduced cells were
selected with puromycin (4 mg/ml).
Statistical Analysis
Data were obtained from experiments performed in triplicates
and repeated at least three times, and results are expressed as
geometric mean 6 SD. Statistical significance was determined
using a Mann-Whitney U test and P values ,0.05 were considered
statistically significant.
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